Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
FDA Oncology Update
Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation
Read More
FDA Oncology Update
FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma
Read More
FDA Oncology Update
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma
Read More
FDA Oncology Update
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer
Read More
FDA Oncology Update
Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program
Read More
FDA Oncology Update
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Read More
FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Read More
FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Read More
FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Read More
FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Read More
1
2
3
4
5
Page 2 of 26
Results 11 - 20 of 253